Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06536257 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalised Immunotherapy Platform

Study acronym: PIP-PREDICT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 24 words Secondary endpoints: details revised at 6 of 24 entries · Site details revised at 1 of 3 sites · Publications: details revised at 3 of 3 entries Show 3 more changesShow less
    • Secondary endpoints: details revised at 6 of 24 entries
    • Site details revised at 1 of 3 sites
    • Publications: details revised at 3 of 3 entries
  2. Re-verified, no change to tracked fieldsv3
  3. Study title shortened, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice.
Trial Details
NCT Number NCT06536257
Lead Sponsor Melanoma Institute Australia
Conditions Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Solid Tumor
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov